Table 1 Clinical characteristics of new-onset MG patients after COVID-19 outbreak
From: The characteristics of new-onset myasthenia gravis after COVID-19 outbreak: a cross-sectional study
Variables | Before COVID-19 outbreak (n = 165) | After COVID-19 outbreak (n = 194) | P value |
|---|---|---|---|
Gender, female, n (%) | 94 (56.97) | 105 (54.12) | 0.589 |
BMI (mean ± SD) | 21.94 ± 4.36 | 21.78 ± 3.75 | 0.706 |
Vaccination, ≥ 1, n (%) | 133 (80.61) | 171 (88.14) | 0.048* |
Infection rate, n (%) | 158 (95.76) | 185 (95.36) | 0.856 |
Age at onset (y), median (IQR) | 43 (24, 55) | 41 (23, 55) | 0.916 |
 Ocular MG | 33 (14.5, 53.75) | 37 (18, 54) | 0.014* |
 Generalized MG | 48 (31.5, 56) | 43 (35, 55) | 0.605 |
Age at time of diagnosis (y), median (IQR) | 44 (26, 55) | 42 (24.75, 55) | 0.880 |
MG duration (w), median (IQR) | 12 (5, 23) | 15 (5.75, 32) | 0.024* |
Smoking, n (%) | 33 (20) | 30 (15.46) | 0.260 |
Hospitalized, n (%) | 65 (39.39) | 72 (37.11) | 0.658 |
MGFA | Â | Â | 0.048* |
 I, n (%) | 72 (43.64) | 107 (55.15) | 0.030* |
 II, n (%) | 55 (33.33) | 44 (22.68) | 0.024* |
≥ III, n (%) | 38 (23.03) | 43 (22.17) | 0.845 |
Clinical phenotype | Â | Â | 0.030* |
 Ocular, n (%) | 72 (43.64) | 107 (55.15) |  |
 Generalized, n (%) | 93 (56.36) | 87 (44.85) |  |
Affect bulbar or respiratory muscles, n (%) | 58 (35.15) | 46 (26.74) | 0.017* |
Affect limb muscles, n (%) | 35 (21.21) | 41 (23.84) | 0.986 |
Antibody status (missed 5) | Â | Â | 0.161 |
 AChRab +, n (%) | 113 (69.33) | 137 (71.73) |  |
 MuSKab +, n (%) | 11 (6.74) | 16 (8.38) |  |
 LRP4ab + or RyR ab + or Titin ab +, n (%) | 0 (0) | 4 (2.09) |  |
Seronegative, n (%) | 39 (23.93) | 34 (17.80) | Â |
Abnormal thymus (missed 1), n (%) | 63 (38.18) | 69 (35.75) | 0.635 |
Thymectomy, n (%) | 36 (21.82) | 27 (13.92) | 0.0498 |
Thymoma histology (22 = before and 16 = after), n (%) |  |  | 0.028 |
 A or AB | 3 (13.63) | 8 (50) |  |
 B | 19 (86.37) | 8 (50) |  |
RNS + (missed 22), n (%) | 73 (46.79) | 88 (48.62) | 0.738 |
MG treatment | Â | Â | Â |
 Pyridostigmine, n (%) | 155 (93.94) | 187 (93.39) | 0.276 |
 Prednisolone, n (%) | 85 (51.52) | 136 (70.10) |  < 0.001* |
 Immunosuppressants, n (%) | 30 (18.18) | 47 (24.23) | 0.164 |
AZA, n (%) | 10 (6.06) | 6 (3.09) | 0.174 |
MMF, n (%) | 6 (3.64) | 10 (5.15) | 0.487 |
 Tacrolimus, n (%) | 14 (8.48) | 31 (15.98) | 0.033* |
Baseline MG-ADL, median (IQR) | 5 (3, 7) | 3 (3, 6) | 0.003* |
Baseline QMGS, median (IQR) | 9 (6, 12) | 7 (5, 8) |  < 0.001* |
Clinical improvement, n (%) | 125 (75.76) | 123 (63.40) | 0.012* |
CT lung inflammation of inpatients (before = 65 and after = 72), n (%) | 13 (20.00) | 29(40.28) | 0.010* |
Pyridostigmine in outpatient treatment (before = 100 and after = 122), n (%) | 91 (91.00) | 119 (97.54) | 0.032* |
Antibody status of outpatients (missed 2, before = 100 and after = 122), Seronegative, n (%) | 27 (27.00) | 19 (15.83) | 0.043* |